Intratympanic dexamethasone as initial therapy for idiopathic sudden sensorineural hearing loss: Clinical evaluation and laboratory investigation

2011 ◽  
Vol 38 (2) ◽  
pp. 165-171 ◽  
Author(s):  
Yaoyao Fu ◽  
Hui Zhao ◽  
Tianyu Zhang ◽  
Fanglu Chi
2015 ◽  
Vol 36 (8) ◽  
pp. 1321-1327 ◽  
Author(s):  
Thomas H. Alexander ◽  
Jeffrey P. Harris ◽  
Quyen T. Nguyen ◽  
Nopawan Vorasubin

2005 ◽  
Vol 132 (6) ◽  
pp. 902-905 ◽  
Author(s):  
Robert A. Battista

OBJECTIVES: To determine hearing recovery by using intratympanic dexamethasone for profound, idiopathic sudden sensorineural hearing loss (ISSNHL). STUDY DESIGN AND SETTING: A prospective, clinical study was performed of 25 consecutive patients seen with profound ISSNHL. Patients received 4 intratympanic treatments of dexamethasone over the course of 2 weeks. Complete hearing recovery was defined as the final pure-tone average (PTA) within 10 dB of baseline. Partial recovery was defined as a final PTA with >50% hearing. The hearing in the contralateral ear was used as baseline. RESULTS: The average time to treatment was 28 days. Two patients had significant hearing recovery, and 1 additional patient had partial recovery. The 2 patients with significant hearing recovery were treated within 9 days of onset of hearing loss. CONCLUSIONS: By using the treatment protocol and definition of hearing recovery of this study, intratympanic dexamethasone does not result in significant hearing improvement for patients with profound ISSNHL. There is a possible trend for improved hearing results if intratympanic treatment is performed within 11 days of onset of hearing loss.


Sign in / Sign up

Export Citation Format

Share Document